A citation-based method for searching scientific literature

Thomas Kaley, Igor Barani, Marc Chamberlain, Michael McDermott, Katherine Panageas, Jeffrey Raizer, Leland Rogers, David Schiff, Michael Vogelbaum, Damien Weber, Patrick Wen. Neuro Oncol 2014
Times Cited: 125







List of co-cited articles
699 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic,[...]. Neuro Oncol 2015
143
46

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum. J Neurosurg 2015
304
34

Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Victoria E Clark, E Zeynep Erson-Omay, Akdes Serin, Jun Yin, Justin Cotney, Koray Ozduman, Timuçin Avşar, Jie Li, Phillip B Murray, Octavian Henegariu,[...]. Science 2013
486
32

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
32

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Priscilla K Brastianos, Peleg M Horowitz, Sandro Santagata, Robert T Jones, Aaron McKenna, Gad Getz, Keith L Ligon, Emanuele Palescandolo, Paul Van Hummelen, Matthew D Ducar,[...]. Nat Genet 2013
377
30


EANO guidelines for the diagnosis and treatment of meningiomas.
Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen,[...]. Lancet Oncol 2016
377
27

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper,[...]. Lancet Oncol 2017
330
26

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Emil Lou, Ashley L Sumrall, Scott Turner, Katherine B Peters, Annick Desjardins, James J Vredenburgh, Roger E McLendon, James E Herndon, Frances McSherry, Julie Norfleet,[...]. J Neurooncol 2012
114
25

A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard, Jeffrey T Williams, Mythili Shastry, Howard A Burris, John D Hainsworth. J Neurooncol 2016
50
50

Atypical and anaplastic meningiomas treated with bevacizumab.
Lakshmi Nayak, Fabio M Iwamoto, Jeremy D Rudnick, Andrew D Norden, Eudocia Quant Lee, Jan Drappatz, Antonio Omuro, Thomas J Kaley. J Neurooncol 2012
110
23

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.
Jeffrey J Raizer, Sean A Grimm, Alfred Rademaker, James P Chandler, Kenji Muro, Irene Helenowski, Laurie Rice, Katie McCarthy, Sandra K Johnston, Maciej M Mrugala,[...]. J Neurooncol 2014
61
34

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
Marc C Chamberlain, Michael J Glantz, Camilo E Fadul. Neurology 2007
120
21

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher,[...]. J Natl Cancer Inst 2015
188
21

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.
Yongli Ji, Cathryn Rankin, Steven Grunberg, Andy E Sherrod, Jamshid Ahmadi, Jeannette J Townsend, Lynn G Feun, Ruth K Fredericks, Christy A Russell, Fairooz F Kabbinavar,[...]. J Clin Oncol 2015
65
29

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Malak Abedalthagafi, Wenya Linda Bi, Ayal A Aizer, Parker H Merrill, Ryan Brewster, Pankaj K Agarwalla, Marc L Listewnik, Dora Dias-Santagata, Aaron R Thorner, Paul Van Hummelen,[...]. Neuro Oncol 2016
148
19

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Andrew D Norden, Jeffrey J Raizer, Lauren E Abrey, Kathleen R Lamborn, Andrew B Lassman, Susan M Chang, W K Alfred Yung, Mark R Gilbert, Howard A Fine, Minesh Mehta,[...]. J Neurooncol 2010
108
18

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, Andrew D Norden, Timothy F Cloughesy, Lauren E Abrey, Howard A Fine, Susan M Chang, H Ian Robins, Karen Fink,[...]. Neuro Oncol 2009
90
20

High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Stéphane Goutagny, Jean C Nault, Maxime Mallet, Dominique Henin, Jessica Z Rossi, Michel Kalamarides. Brain Pathol 2014
158
18

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
Julia Furtner, Veronika Schöpf, Katharina Seystahl, Emilie Le Rhun, Roberta Rudà, Ulrich Roelcke, Susanne Koeppen, Anna Sophie Berghoff, Christine Marosi, Paul Clement,[...]. Neuro Oncol 2016
36
47

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Andrew D Norden, Keith L Ligon, Samantha N Hammond, Alona Muzikansky, David A Reardon, Thomas J Kaley, Tracy T Batchelor, Scott R Plotkin, Jeffrey J Raizer, Eric T Wong,[...]. Neurology 2015
51
33

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
16

Epidemiology and etiology of meningioma.
Joseph Wiemels, Margaret Wrensch, Elizabeth B Claus. J Neurooncol 2010
585
16

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Marta Simó, Andreas A Argyriou, Miquel Macià, Gerard Plans, Carles Majós, Noemi Vidal, Miguel Gil, Jordi Bruna. Cancer Chemother Pharmacol 2014
40
40


Temozolomide for treatment-resistant recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. Neurology 2004
101
15

Trabectedin has promising antineoplastic activity in high-grade meningioma.
Matthias Preusser, Sabine Spiegl-Kreinecker, Daniela Lötsch, Adelheid Wöhrer, Maria Schmook, Karin Dieckmann, Walter Saringer, Christine Marosi, Walter Berger. Cancer 2012
43
34

Medical therapies for meningiomas.
Patrick Y Wen, Eudocia Quant, Jan Drappatz, Rameen Beroukhim, Andrew D Norden. J Neurooncol 2010
101
15

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, Hadrien Peyrière, Noémie Basset, Didier Autran, Catherine Roche, Michel Kalamarides,[...]. Clin Cancer Res 2020
39
38

Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.
M H Ruttledge, J Sarrazin, S Rangaratnam, C M Phelan, E Twist, P Merel, O Delattre, G Thomas, M Nordenskjöld, V P Collins. Nat Genet 1994
443
14

Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Victoria E Clark, Akdes Serin Harmancı, Hanwen Bai, Mark W Youngblood, Tong Ihn Lee, Jacob F Baranoski, A Gulhan Ercan-Sencicek, Brian J Abraham, Abraham S Weintraub, Denes Hnisz,[...]. Nat Genet 2016
171
14

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.
Raymond Y Huang, Wenya Linda Bi, Michael Weller, Thomas Kaley, Jaishri Blakeley, Ian Dunn, Evanthia Galanis, Matthias Preusser, Michael McDermott, Leland Rogers,[...]. Neuro Oncol 2019
55
25


NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
Marianne F James, Sangyeul Han, Carolyn Polizzano, Scott R Plotkin, Brendan D Manning, Anat O Stemmer-Rachamimov, James F Gusella, Vijaya Ramesh. Mol Cell Biol 2009
185
13

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
Ziming Du, Malak Abedalthagafi, Ayal A Aizer, Allison R McHenry, Heather H Sun, Mark-Anthony Bray, Omar Viramontes, Revaz Machaidze, Priscilla K Brastianos, David A Reardon,[...]. Oncotarget 2015
87
14

An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas.
Sam Q Sun, Ammar H Hawasli, Jiayi Huang, Michael R Chicoine, Albert H Kim. Neurosurg Focus 2015
81
16

mTORC1 inhibitors suppress meningioma growth in mouse models.
Doreen Pachow, Nadine Andrae, Nadine Kliese, Frank Angenstein, Oliver Stork, Annette Wilisch-Neumann, Elmar Kirches, Christian Mawrin. Clin Cancer Res 2013
68
19

Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.
Leland Rogers, Peixin Zhang, Michael A Vogelbaum, Arie Perry, Lynn S Ashby, Jignesh M Modi, Anthony M Alleman, James Galvin, David Brachman, Joseph M Jenrette,[...]. J Neurosurg 2018
110
13

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
David E Reuss, Rosario M Piro, David T W Jones, Matthias Simon, Ralf Ketter, Marcel Kool, Albert Becker, Felix Sahm, Stefan Pusch, Jochen Meyer,[...]. Acta Neuropathol 2013
146
12

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
Ganesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, Parker H Merrill, Naema Nayyar, Corey M Gill, Ryan Brewster, Wenya Linda Bi, Pankaj K Agarwalla, Aaron R Thorner,[...]. Neuro Oncol 2017
67
17

BAP1 mutations in high-grade meningioma: implications for patient care.
Ganesh M Shankar, Sandro Santagata. Neuro Oncol 2017
80
15

Genomic landscape of high-grade meningiomas.
Wenya Linda Bi, Noah F Greenwald, Malak Abedalthagafi, Jeremiah Wala, Will J Gibson, Pankaj K Agarwalla, Peleg Horowitz, Steven E Schumacher, Ekaterina Esaulova, Yu Mei,[...]. NPJ Genom Med 2017
85
14

Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.
Adriana Olar, Khalida M Wani, Charmaine D Wilson, Gelareh Zadeh, Franco DeMonte, David T W Jones, Stefan M Pfister, Erik P Sulman, Kenneth D Aldape. Acta Neuropathol 2017
71
16

Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
Katharina Seystahl, Veit Stoecklein, Ulrich Schüller, Elisabeth Rushing, Guillaume Nicolas, Niklaus Schäfer, Harun Ilhan, Athina Pangalu, Michael Weller, Jörg-Christian Tonn,[...]. Neuro Oncol 2016
56
21

Salvage chemotherapy with CPT-11 for recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. J Neurooncol 2006
64
17

WHO grade II and III meningiomas: a study of prognostic factors.
Anne Durand, François Labrousse, Anne Jouvet, Luc Bauchet, Michel Kalamaridès, Philippe Menei, Robert Deruty, Jean Jacques Moreau, Michelle Fèvre-Montange, Jacques Guyotat. J Neurooncol 2009
202
11

Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
J Boström, B Meyer-Puttlitz, M Wolter, B Blaschke, R G Weber, P Lichter, K Ichimura, V P Collins, G Reifenberger. Am J Pathol 2001
179
11

Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
Christian Mawrin, Tina Sasse, Elmar Kirches, Siegfried Kropf, Thomas Schneider, Christoph Grimm, Claudia Pambor, Christian K Vorwerk, Raimund Firsching, Uwe Lendeckel,[...]. Clin Cancer Res 2005
91
12

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
Seunggu J Han, Gerald Reis, Gary Kohanbash, Shruti Shrivastav, Stephen T Magill, Annette M Molinaro, Michael W McDermott, Philip V Theodosopoulos, Manish K Aghi, Mitchel S Berger,[...]. J Neurooncol 2016
55
20

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
Derek R Johnson, David W Kimmel, Patrick A Burch, Terrence L Cascino, Caterina Giannini, Wenting Wu, Jan C Buckner. Neuro Oncol 2011
52
19


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.